Selected phenotypic and functional changes in ovarian cancer cells treated in vitro with combined therapy using cisplatin and hyperthermia
 
More details
Hide details
1
Zakład Biotechnologii i Inżynierii Genetycznej, Wydział Nauk Farmaceutycznych w Sosnowcu, Śląski Uniwersytet Medyczny w Katowicach / Department of Biotechnology and Genetic Engineering, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland
 
 
Corresponding author
Aleksandra Zoń   

Zakład Biotechnologii i Inżynierii Genetycznej, Wydział Nauk Farmaceutycznych w Sosnowcu, Śląski Uniwersytet Medyczny w Katowicach, ul. Jedności 8, 41-200 Sosnowiec
 
 
Ann. Acad. Med. Siles. 2023;77:115-127
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The typical treatment strategy used for ovarian cancer is surgery followed by chemotherapy using cytostatic drugs, including cisplatin. Unfortunately, the majority of patients experience a relapse of the disease, the main reason for which is the development of cisplatin resistance. Due to this, new treatment strategies are being sought, including combination therapy, an example of which is the simultaneous treatment of cells with a cytostatic drug and hyperthermia. The aim of the study was to assess the occurrence of phenotypic and functional changes in ovarian cancer cells treated with cisplatin and/or moderate hyperthermia.

Material and methods:
Ovarian cancer cell lines SKOV-3 and TOV-21G were stimulated to apoptosis using cis-diammineplatinum(II) dichloride. Subsequently, the cells were subjected to hyperthermia by placing them in temperatures of 39°C, 40°C and a standard temperature of 37°C. Phenotypic changes within the cells were verified by fluorescent staining with acridine orange, ethidium bromide and DAPI (4′,6-diamidino-2-phenylindole). Functional changes related to in vitro cell migration were analyzed with the wound healing assay.

Results:
It was shown that the effect of cisplatin on the cells led to death by apoptosis, whereby the effect of potentiating the action of the cytostatic agent by the use of moderate hyperthermia was noticed. In addition, in the case of cells of the SKOV-3 line treated with the aforementioned agents, a statistically significant decrease in cell migration was observed in relation to the population of control cells.

Conclusions:
The obtained results indicate that the treatment of ovarian cancer cells with cisplatin and moderate hyperthermia leads to the appearance of phenotypic changes in these cells, characteristic of apoptotic processes. In addition, the application of both agents induces such changes in the cells that reduce cell migration, thereby reducing the metastatic potential of ovarian cancer cells.

 
REFERENCES (15)
1.
Global Cancer Observatory: Cancer Today, 2020. J. Ferlay, M. Ervik, F. Lam, M. Colombet, L. Mery, M. Piñeros, A. Znaor, I. Soerjomataram, F. Bray [red.] [online] https://gco.iarc.fr/today [dostęp: 15.11.2022].
 
2.
Global Cancer Observatory: Cancer Tomorrow, 2020. J. Ferlay, M. Laversanne, M. Ervik, F. Lam, M. Colombet, L. Mery, M. Piñeros, A. Znaor, I. Soerjomataram, F. Bray [red.] [online] https://gco.iarc.fr/tomorrow [dostęp: 15.11.2022].
 
3.
Stewart C., Ralyea C., Lockwood S. Ovarian cancer: an integrated review. Semin. Oncol. Nurs. 2019; 35(2): 151–156, doi: 10.1016/j.soncn.2019.02.001.
 
4.
Chandra A., Pius C., Nabeel M., Nair M., Vishwanatha J.K., Ahmad S., Basha R. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019; 8(16): 7018–7031, doi: 10.1002/cam4.2560.
 
5.
Cortez A.J., Tudrej P., Kujawa K.A., Lisowska K.M. Advances in ovarian cancer therapy. Cancer Chemother. Pharmacol. 2018; 81(1): 17–38, doi: 10.1007/s00280-017-3501-8.
 
6.
Bieg D., Sypniewski D., Nowak E., Bednarek I. MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch. Gynecol. Obstet. 2019; 299(4): 1077–1087, doi: 10.1007/s00404-018-4999-7.
 
7.
Bieg D., Sypniewski D., Nowak E., Bednarek I. Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch. Gynecol. Obstet. 2018; 298(6): 1181–1194, doi: 10.1007/s00404-018-4912-4.
 
8.
Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg. Chem. 2019; 88: 102925, doi: 10.1016/j.bioorg.2019.102925.
 
9.
Rocha C.R.R., Silva M.M., Quinet A., Cabral-Neto J.B., Menck C.F.M. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo) 2018; 73(suppl 1): e478s, doi: 10.6061/clinics/2018/e478s.
 
10.
Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol. Oncol. 2019; 53(2): 148–158, doi: 10.2478/raon-2019-0018.
 
11.
Ortiz M., Wabel E., Mitchell K., Horibata S. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist. 2022; 5(2): 304–316, doi: 10.20517/cdr.2021.147.
 
12.
Borkar P., Bhandari P., Yadav S., Prabhu A. Cisplatin resistance in ovarian cancer: classical outlook and newer perspective. Biomed. Pharmacol. J. 2021; 14(4): 1993–2005, doi: 10.13005/bpj/2297.
 
13.
Shetake N.G., Pandey B.N. Hyperthermia therapy of cancer: need for deeper biological insights for improved therapeutic outcome. J. Radiat. Cancer Res. 2019; 10(4): 170–173, doi: 10.4103/jrcr.jrcr_2_20.
 
14.
Aseervatham J. Cytoskeletal remodeling in cancer. Biology 2020; 9(11): 385, doi: 10.3390/biology9110385.
 
15.
Shimizu T., Fujii T., Sakai H. The relationship between actin cytoskeleton and membrane transporters in cisplatin resistance of cancer cells. Front. Cell Dev. Biol. 2020; 8: 597835, doi: 10.3389/fcell.2020.597835.
 
eISSN:1734-025X
Journals System - logo
Scroll to top